The GLP-1 blind spot: Why the FDA’s new eye stroke warning matters

It forces the medical community to treat these therapies with clinical gravity instead of casual enthusiasm.
This is a brief. The reporting belongs to The Hill — read the complete story, with full context and credits, at the source.
Read the full story at The Hill ↗thehill.com
More from the Health desk
Just in

Canary island erects field hospital amid migrant influx
Just in

148 aboard Florida-bound cruise ship sickened by ‘unknown’ GI outbreak: CDC

STAT+: Lawmakers want U.S. biotech to outcompete China

STAT+: Peptide market poised to explode with new Hims and Noom launches

Two-hour ambulance target missed more than 2,000 times
